Short Interest in Strata Skin Sciences, Inc. (NASDAQ:SSKN) Grows By 33.4%

Strata Skin Sciences, Inc. (NASDAQ:SSKN) saw a significant increase in short interest in the month of January. As of January 30th, there was short interest totaling 358,994 shares, an increase of 33.4% from the January 15th total of 269,078 shares. Approximately 10.3% of the company’s shares are sold short. Based on an average daily trading volume, of 73,243 shares, the days-to-cover ratio is presently 4.9 days. Based on an average daily trading volume, of 73,243 shares, the days-to-cover ratio is presently 4.9 days. Approximately 10.3% of the company’s shares are sold short.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on SSKN shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Strata Skin Sciences in a research report on Thursday, January 22nd. Wall Street Zen upgraded Strata Skin Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Strata Skin Sciences currently has a consensus rating of “Hold” and an average price target of $6.00.

Institutional Investors Weigh In On Strata Skin Sciences

An institutional investor recently bought a new position in Strata Skin Sciences stock. Susquehanna International Group LLP acquired a new stake in Strata Skin Sciences, Inc. (NASDAQ:SSKN) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 12,426 shares of the medical device company’s stock, valued at approximately $26,000. Susquehanna International Group LLP owned 0.24% of Strata Skin Sciences as of its most recent filing with the Securities and Exchange Commission. 32.43% of the stock is owned by hedge funds and other institutional investors.

Strata Skin Sciences Stock Down 8.3%

Shares of NASDAQ:SSKN traded down $0.03 during trading on Tuesday, hitting $0.32. The company’s stock had a trading volume of 9,791,465 shares, compared to its average volume of 648,746. Strata Skin Sciences has a fifty-two week low of $0.26 and a fifty-two week high of $3.86. The business has a 50 day moving average price of $1.22 and a two-hundred day moving average price of $1.57. The company has a debt-to-equity ratio of 10.22, a quick ratio of 0.75 and a current ratio of 0.95. The company has a market capitalization of $1.86 million, a PE ratio of -0.12 and a beta of 0.33.

About Strata Skin Sciences

Strata Skin Sciences, Inc is a medical technology company headquartered in Edison, New Jersey, that specializes in developing and commercializing dermatological devices and therapies. The company’s flagship offering is the XTRAC® excimer laser system, an FDA‐cleared, 308-nanometer ultraviolet light device used to treat skin conditions such as vitiligo and psoriasis. Strata’s product suite also includes associated accessories and disposables, as well as clinical services and training programs designed to support dermatology practices and improve patient outcomes.

Strata Skin Sciences expanded its portfolio and market presence through the strategic acquisition of PhotoMedex in 2019, bringing together complementary phototherapy and energy-based technologies under one roof.